Professor Matthew Murray
Position: Professor
Personal home page:
https://www.researchgate.net/profile/Matthew_Murray
PubMed journal articles - click here
Professor Matthew Murray is pleased to consider applications from prospective PhD students.
Our lab is undertaking a national Children's Cancer and Leukaemia Group (CCLG) approved study, investigating non-coding RNAs, including microRNAs (miR-), in malignant germ cell tumours and other childhood cancers. Our lab has a particular interest in circulating microRNA biomarkers, with a particular focus on germ cell tumours.
Symplectic Elements feed provided by Research Information, University of Cambridge
1. Angus Hodder, Sarah M Leiter, Jonathan Kennedy, Dilys Addy, Thankamma Ajithkumar, Kieren Allinson, Phil Ancliff, Shivani Bailey, Gemma Barnard, GA Amos Burke, Charlotte Burns, Julian Cano-Flanagan, Jane Chalker, Nicholas Coleman, Danny Cheng, Yasmin Clinch, Caryl Dryden, Sara Ghorashian, Blanche Griffin, Gail Horan, Michael Hubank, Philippa May, Joanna McDerra, Rajvi Nagrecha, James C. Nicholson, David O’Connor, Vesna Pavasovic, Annelies Quaegebeur, Anupama Rao, Tom Roberts, Iryna Stasevich, John A Tadross, Claire Trayers, Jamie Trotman, Ajay Vora, James Watkins, Lyn Chitty, Sarah Bowdin, Ruth Armstrong, Murray MJ*, Catherine E Hook*, Patrick Tarpey*, Aditi Vedi*, Jack Bartram*, Sam Behjati*. Practice changing benefits from routine whole genome sequencing for children with cancer. Nature Medicine, 2024 Jul;30(7):1905-1912. doi: 10.1038/s41591-024-03056-w. Epub 2024 Jul 2. *Co-corresponding.
2. Diezi M, Pizer B, Murray MJ, on behalf of the SIOPE Brain Tumour Group Central Nervous System Germ Cell Tumour Subgroup. Overview of current European practice for the management of patients with intracranial germ cell tumours. European Journal of Cancer Paediatric Oncology, 2024, Volume 3, 100146, June 2024. Published: February 06, 2024. DOI: https://doi.org/10.1016/j.ejcped.2024.100146
3. Pashankar F*, Murray MJ*, Gell J, Macdonald N, Shamash J, Klosterkemper L, Olson T, Hirsch M, Lockley M, Sara Stoneham S, Frazier AL. Consensus and controversy in the management of pediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective. *joint first authors. eClinicalMedicine, 2024 Feb 6;69:102453. doi: 10.1016/j.eclinm.2024.102453. eCollection 2024 Mar.
4. Alonso-Crisostomo L, Trendell J, Ferraresso M, Bailey S, Ward D, Scurlock ZGL, Wenlock SC, Bastos CAP, Jugdaohsingh R, Faria NJ, Enright AJ, Scarpini CG, Coleman N*, Murray MJ*C. Testicular germ cell tumour cells release microRNA-containing extracellular vesicles that induce phenotypic and genotypic changes in cells of the tumour microenvironment. International Journal of Cancer, 2024 Jan 15;154(2):372-388. doi: 10.1002/ijc.34697. Epub 2023 Aug 26.
5. Bailey S, Ferraresso MF, Alonso-Crisostomo L, Ward D, Smith S, Nicholson JC, Saini HK, Enright AJ, Scarpini CG*, Coleman N*, Murray MJ*. Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption. *Joint senior authors. British Journal of Cancer, 2023 Oct;129(9):1451-1461. doi: 10.1038/s41416-023-02453-1. Epub 2023 Oct 3.
6. Lafin JT, Scarpini CG, Amini A, Konneh B, Howard JM, Gerald T, Nuno M, Piao J, Savelyeva A, Wang Z, Jeffrey Gagan, Jia L, Lewis CM, Murray S, Sawa YC, Margulis V, Woldu SL, Strand DW, Coleman N, Amatruda JF, Frazier AL, Murray MJ, Bagrodia A. Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range. Scientific Reports, 2023, June 29;13(1):10558. doi: 10.1038/s41598-023-37271-1.
7. Benlhachemi S, Abouqal R, Coleman N, Murray MJ, Khattab M, El Fahime E. Circulating microRNAs profiles in Wilms tumour (WT): A systematic review and meta-analysis of diagnostic test accuracy. Non-coding RNA Research, 2023, 8 (2023) 413–425. https://doi.org/10.1016/j.ncrna.2023.05.007
8. Murray MJ, Scarpini CG, Coleman N. Serum tumour markers for testicular cancer recurrence. Nature Reviews Urology, 2023 Aug;20(8):459-460. doi: 10.1038/s41585-023-00782-7.
9. Laidlaw S, Crisostomo LA, Bailey S, Saini HK, Molnár A, Nicholson JC, Enright AJ, Scarpini CG, Rahbari R, Coleman N, Murray MJ. Small non-coding RNA sequencing reveals global dysregulation of piwi-interacting RNAs (piRNAs) in gonadal malignant germ cell tumours. Andrology, 2023 May;11(4):738-755. doi: 10.1111/andr.13312. Epub 2022 Oct 26.
10. Fonseca A, Lobo J, Hazard FKG, Gell J, Nicholls P, Weiss R, Klosterkemper L, Volchenboum S, James C. Nicholson JC, Frazier AL, Amatruda JF, Bagrodia A, Lockley M, Murray MJ. Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium. British Journal of Cancer, 2022 Nov;127(9):1577-1583. doi: 10.1038/s41416-022-02000-4. Epub 2022 Oct 13.
11. Chadda KR, Blakey EE, Coleman N, Murray MJC. The clinical utility of dysregulated microRNA expression in paediatric solid tumours. European Journal of Cancer, 2022 Nov;176:133-154. doi: 10.1016/j.ejca.2022.09.010. Epub 2022 Oct 7.
12. Oliver TRW, Chappell L, Sanghvi R, Deighton L, Ansari-Pour N, Dentro SC, Neville M, Young MD, Coorens THH, Jung H, Butler T, Leongamornlet D, Sanders M, Hooks Y, Cagan A, Mitchell TJ, Cortes-Ciriano I, Warren AY, Wedge D, Heer R, Coleman N, Murray MJ, Campbell PJ, Rahbari R, Behjati S. Clonal diversification and histogenesis of malignant germ cell tumours. Nature Communications, 2022 Aug 11;13(1):4272. doi: 10.1038/s41467-022-31375-4.
13. Morana G, Shaw D, MacDonald SM, Alapetite C, Ajithkumar T, Bhatia A, Brisse H, Jaimes C, Czech T, Dhall G, Fangusaro J, Faure-Conter C, Fouladi M, Hargrave D, Harreld J, Mitra D, Nicholson JC, Souweidane M, Timmermann B, Calaminus G, Bartels U, Bison B, Murray MJC. Imaging response assessment for Central Nervous System Germ Cell Tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children’s Oncology Group. Lancet Oncology, 2022, May;23(5):e218-e228. doi: 10.1016/S1470-2045(22)00063-8.
14. Trotman J, Armstrong A, Firth H, Trayers C, Watkins J, Allinson K, Jacques TS, Nicholson JC, Burke GAA, Sam Behjati S*, Murray MJ*, Hook CE*, Tarpey P*, on behalf of Genomics England Research Consortium. The NHS England 100,000 Genomes Project – Feasibility and utility of centralised genome sequencing for children with cancer. British Journal Cancer, 2022 Jul;127(1):137-144. doi: 10.1038/s41416-022-01788-5. Epub 2022 Apr 22. *Joint senior and co-corresponding authors.
15. Murray MJ, Moleron R, Adamski J, English M, Burke GAA, Cross J, Ajithkumar T, Stoneham S, Nicholson JC. Vinblastine monotherapy induction prior to radiotherapy for patients with intracranial germinoma during the COVID-19 pandemic. Pediatric Blood & Cancer, 2022 Jan;69(1):e29359. doi: 10.1002/pbc.29359. Epub 2021 Sep 14.
16. Piao J, Lafin L, Scarpini CG, Nuno M, Syring I, Dieckmann KP, Belge G, Ellinger J, Amatruda JF, Bagrodia A, Krailo MD, Coleman N, Frazier AL, Murray MJ. A multi-institutional pooled analysis demonstrates the utility of circulating miR-371a-3p alone for testicular malignant germ cell tumour diagnosis. Clinical Genitourinary Cancer, 2021 Dec;19(6):469-479. doi: 10.1016/j.clgc.2021.08.006. Epub 2021 Sep 15.
17. Fern LA, Greenwood M, Smith S, Brand S, Coleman N, Stark DP, Murray MJ. Pre-implementation assessment of the acceptability of using circulating microRNAs for follow-up of malignant germ-cell-tumours. Clinical Genitourinary Cancer, 2021 Oct;19(5):381-387. doi: 10.1016/j.clgc.2021.03.005. Epub 2021 Mar 17.
18. Murray MJ, Scarpini CG, Coleman N. A circulating microRNA panel for malignant germ cell tumor diagnosis and monitoring. Protocol Chapter. Editor: Aditya Bagrodia and James Amatruda. Title: Testicular Germ Cell Tumors. Methods in Molecular Biology, 2021;2195:225-243. doi: 10.1007/978-1-0716-0860-9_15.
19. Murray MJC, Smith S, Ward D, Verduci L, Nicholson JC, Scarpini CG, Coleman N. Circulating microRNAs as biomarkers to assist the management of the malignant germ cell tumour subtype choriocarcinoma. Translational Oncology, 2021;14:100904.
20. Murray MJ, Ajithkumar TV, Harris F, Williams RM, Jalloh I, Cross J, Ronghe M, Ward DM, Scarpini CG, Nicholson JC* and Nicholas Coleman, on behalf of the CCLG. Clinical utility of circulating miR-371a-3p for the management of patients with intracranial malignant germ cell tumors. Neuro-Oncology Advances, 2020 Apr 13;2(1):vdaa048. doi: 10.1093/noajnl/vdaa048. eCollection 2020 Jan-Dec.
21. Murray MJ, Ruffle A, Lowis S, Howell L, Whitton S, Dommett R, Gamble A, Shenton G, Nicholson JC. A Delphi method to identify expert opinion to support NICE children’s cancer referral guidelines. Archives of Disease in Childhood, 2020;105:241-246.
22. Lafin JT, Singla N, Woldu S, Lotan Y, Lewis CM, Majmudar K, Zhou M, Kapur P, Margulis V, Murray MJ, Amatruda JF, Bagrodia A. Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection. European Urology, 2020;77:290-292.
23. Murray MJ, Coleman N. Can circulating microRNAs quantification solve clinical dilemmas in testicular germ cell malignancy? Nature Reviews Urology, 2019;16:505-506.
24. Charytonowicz D, Aubrey H, Bell C, Ferret M, Tsui K, Atfield R, Coleman N*, Murray MJ*, Wilson E*. A cost analysis of non-invasive blood-based microRNA testing versus CT scans for follow-up in patients with testicular germ cell tumors. Clinical Genitourinary Cancer, 2019;17:e733-e744. *joint senior authors.
25. Murray MJ, Coleman N. Understanding the pathway - MicroRNA dysregulation in malignant germ cell tumors: more than a biomarker? Journal of Clinical Oncology, 2019;37:1432-1435.
26. Murray MJ*, Watson HL*, Ward D, Bailey S, Ferraresso M, Nicholson JC, Gnanapragasam VJ, Thomas B, Scarpini CG, Coleman N. ‘Future-proofing’ blood processing for measurement of circulating microRNAs in samples from biobanks and prospective clinical trials. Cancer Epidemiology, Biomarkers and Prevention, 2018;27:208-218. *joint first authors.
27. Calaminus G, Frappaz D, Kortmann RD, Krefeld B, Saran F, Pietsch T, Vasiljevic A, Garre ML, Ricardi U, Mann JR, Goebel U, Alapetite C, Murray MJ, Nicholson JC. Outcome of patients with intracranial non-germinomatous germ cell tumors - lessons from the SIOP-CNS-GCT-96 trial. Neuro-Oncology, 2017;19:1661-1672.
29. Murray MJ, Bailey S, Heinemann K, Mann J, Göbel UK, Saran S, Hale JP, Calaminus C, Nicholson JC. Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy, International Journal of Cancer, 2017;141:621-635.
30. Murray MJ, Huddart RA, Coleman N. The present and future of serum diagnostic tests for testicular malignant germ cell tumours. Nature Reviews Urology, 2016;13:715-725.
31. Shaikh F, Murray MJ, Amatruda JF, Coleman N, Nicholson JC, Hale JPH, Pashankar F, Stoneham SJ, Poynter JN, Olson TA, Billmire DF, Stark D, Rodriguez-Galindo C, Frazier AL. Paediatric extracranial germ cell tumours. Lancet Oncology, 2016;17:e149-62.
32. Murray MJ, Bell E, et al (2016) A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ cell tumours. British Journal of Cancer, 114:151-62.
33. Murray MJ, Bartels U, et al (2015) Consensus in the management of intracranial germ-cell tumours. Lancet Oncology, 16:e470-7.
34. Olson TA, Murray MJ, et al (2015) Pediatric and Adolescent Extracranial Germ Cell Tumors - The Road to Collaboration. Journal of Clinical Oncology, 33:3018-28.
35. Murray MJ, Raby KL, et al (2015) Solid tumors of childhood display specific serum microRNA profiles. Cancer Epidemiology, Biomarkers & Prevention, 24:350-60.
36. Frazier AL, Hale JP, Rodriguez-Galindo C, Dang H, Olson T, Murray MJ, et al (2015) Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data from the United Kingdom and United States. Journal of Clinical Oncology, 33:195-201.
37. Murray MJ, Bailey S, et al (2014) Serum levels of mature microRNAs in DICER1-mutated pleuropulmonary blastoma. Oncogenesis, 3:e87.
38. Murray MJ, Saini HK, et al (2013) LIN28 expression in malignant germ cell tumors downregulates let-7 and increases oncogene levels. Cancer Research, 73:4872-84.
39. Murray MJ, Coleman N (2012) Testicular cancer: A new generation of biomarkers for malignant germ cell tumours. Nature Reviews Urology, 9:298-300.
40. Murray MJ, Halsall D, et al (2011) Identification of MicroRNAs from the miR-371~373 and miR-302 Clusters as Potential Serum Biomarkers of Malignant Germ Cell Tumors. American Journal of Clinical Pathology, 135:119-125.
41. Palmer RD*, Murray MJ*, et al (2010) Malignant Germ Cell Tumors Display Common MicroRNA Profiles Resulting in Global Changes in Expression of Messenger RNA Targets. Cancer Research, 70:2911-23. *joint first authors
